OpenLB
Open Library of Bioscience
Advanced Search
Life (Basel, Switzerland)
Jul 07, 2022;12 (7):

Does Protocatechuic Acid Affect the Activity of Commonly Used Antibiotics and Antifungals?

Adrian Fifere, Ioana-Andreea Turin-Moleavin, Irina Rosca
Author Information
  1. Adrian Fifere: Centre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni" Institute of Macromolecular Chemistry, 700487 Iasi, Romania.
  2. Ioana-Andreea Turin-Moleavin: Centre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni" Institute of Macromolecular Chemistry, 700487 Iasi, Romania.
  3. Irina Rosca: Centre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni" Institute of Macromolecular Chemistry, 700487 Iasi, Romania. ORCID
PMID: 35888098 DOI: 10.3390/life12071010

Abstract

The aim of this study is to evaluate the efficiency of protocatechuic acid (PCA) in enhancing the commonly used drugs used to fight against nosocomial infection. These drugs are represented by routinely used antibiotics, synthetic chemotherapeutic agents with an antimicrobial spectrum, and antifungals. Three concentrations of PCA were added to 12 types of commercial disks used for antibiotic and antifungal susceptibility and tested against bacterial and yeast strains represented by , , , and . The results proved that PCA increased up to 50% of the antibacterial activity, especially that of levofloxacin against and . These formulations will lead to new drug design ideas containing a smaller amount of antibiotics with the same effectiveness.

Keywords

antibiotics antifungals drug resistance increased activity protocatechuic acid

References

  1. Med Mycol. 2019 Jun 1;57(Supplement_3):S328-S343 [PMID: 31292663]
  2. PLoS Biol. 2020 Jan 27;18(1):e3000612 [PMID: 31986134]
  3. Euro Surveill. 2017 Feb 9;22(6): [PMID: 28205502]
  4. Microb Drug Resist. 2013 Aug;19(4):256-65 [PMID: 23480526]
  5. Nutr J. 2014 Jun 19;13:63 [PMID: 24943896]
  6. Infect Drug Resist. 2021 Mar 03;14:833-839 [PMID: 33688218]
  7. Acta Pol Pharm. 1997 May-Jun;54(3):229-32 [PMID: 9511450]
  8. Antibiotics (Basel). 2020 Aug 04;9(8): [PMID: 32759771]
  9. Int J Antimicrob Agents. 2021 Sep;58(3):106394 [PMID: 34197906]
  10. Acta Pol Pharm. 2015 Jul-Aug;72(4):643-50 [PMID: 26647619]
  11. J Clin Pathol. 1968 Mar;21(2):202-9 [PMID: 5697054]
  12. Biomed Pharmacother. 2022 Feb;146:112498 [PMID: 34953395]
  13. Ther Adv Drug Saf. 2014 Dec;5(6):229-41 [PMID: 25436105]
  14. Clin Pharmacol Ther. 2007 Aug;82(2):204-9 [PMID: 17538551]
  15. Infect Drug Resist. 2021 Jul 24;14:2883-2894 [PMID: 34335034]
  16. Biomedicines. 2020 Apr 28;8(5): [PMID: 32354172]
  17. AMA Arch Intern Med. 1959 Aug;104(2):208-16 [PMID: 13669774]
  18. ISRN Pharmacol. 2014 Mar 26;2014:952943 [PMID: 25006494]
  19. Antioxidants (Basel). 2021 Jun 21;10(6): [PMID: 34205576]
  20. Int J Antimicrob Agents. 2020 Feb;55(2):105834 [PMID: 31682902]
  21. Antiviral Res. 2007 Apr;74(1):59-64 [PMID: 17298850]
  22. PLoS One. 2017 Feb 24;12(2):e0172273 [PMID: 28235054]
  23. Microbiol Spectr. 2021 Dec 22;9(3):e0074321 [PMID: 34908461]
  24. Curr Opin Microbiol. 2018 Oct;45:70-76 [PMID: 29547801]
  25. Pharmaceutics. 2020 May 02;12(5): [PMID: 32370227]
  26. Braz J Microbiol. 2012 Jul;43(3):938-45 [PMID: 24031910]
  27. Clin Chest Med. 2009 Jun;30(2):203-15, v [PMID: 19375628]
  28. Evid Based Complement Alternat Med. 2015;2015:593902 [PMID: 25737736]
  29. Appl Environ Microbiol. 2011 Oct;77(19):6852-7 [PMID: 21821749]
  30. J Appl Microbiol. 2020 Feb;128(2):387-400 [PMID: 31573730]
  31. Foodborne Pathog Dis. 2009 Mar;6(2):201-6 [PMID: 19099360]
  32. iScience. 2020 Apr 24;23(4):100986 [PMID: 32240953]
  33. J Antimicrob Chemother. 2018 Nov 1;73(11):2916-2926 [PMID: 30184207]
  34. Mater Sci Eng C Mater Biol Appl. 2019 Jan 1;94:608-618 [PMID: 30423746]
  35. Clin Microbiol Rev. 1999 Oct;12(4):564-82 [PMID: 10515903]
  36. Pharmaceutics. 2021 Sep 07;13(9): [PMID: 34575489]
  37. Int J Biol Sci. 2010 Sep 21;6(6):556-68 [PMID: 20941374]
  38. J Adv Pharm Technol Res. 2020 Jul-Sep;11(3):113-116 [PMID: 33102193]
  39. Drug Intell Clin Pharm. 1985 Jul-Aug;19(7-8):540-7 [PMID: 3896715]

Grants

  1. 339/390015/25.02.2021/European Social Fund for Regional Development, Competitiveness Operational Programme 2014-2020, Axis 1
  2. PN-III-P1-1.1-TE-2021-0739, within PNCDI III/Ministry of Research, Innovation and Digitization, CNCS - UEFISCDI
Journal Article

Word Cloud

Created with Highcharts 10.0.0usedPCAprotocatechuicaciddrugsrepresentedantibioticsantifungalsincreasedactivitydrugaimstudyevaluateefficiencyenhancingcommonlyfightnosocomialinfectionroutinelysyntheticchemotherapeuticagentsantimicrobialspectrumThreeconcentrationsadded12typescommercialdisksantibioticantifungalsusceptibilitytestedbacterialyeaststrainsresultsproved50%antibacterialespeciallylevofloxacinformulationswillleadnewdesignideascontainingsmalleramounteffectivenessProtocatechuicAcidAffectActivityCommonlyUsedAntibioticsAntifungals?antibioticsresistance

Similar Articles

Cited By